TYA-11018

TYA-11018 is a proprietary **small-molecule histone deacetylase 6 inhibitor** developed by **Tenaya Therapeutics** for cardiovascular disease indications. Preclinical disclosures identify it as a highly specific HDAC6 inhibitor from Tenaya's HDAC6 program, with activity in mouse models of **heart failure with preserved ejection fraction** and **genetic dilated cardiomyopathy**. In these models, HDAC6 inhibition was associated with improved cardiac function, reduced hypertrophy and metabolic abnormalities, and modulation of pathways linked to fibrosis, inflammation, autophagy, and mitochondrial energetics. Publicly available information indicates that TYA-11018 has remained a **preclinical** research-stage compound, while the related program candidate **TN-301** has advanced clinically.